The response includes a considered implementation plan to strengthen the regulation of medical devices and in vitro diagnostics, improve patient safety, and foster innovation post-Brexit.
On 26 June 2022, the UK Medicines and Healthcare products Regulatory Agency (MHRA) published its long-awaited response to its consultation on the UK’s post-Brexit regulatory regime for medical devices and in vitro diagnostic (IVD) medical devices. The 10-week public consultation concluded in November 2021. The response factors in feedback and observations from almost 900 respondents, including views from industry, the wider healthcare sector, and patients.
Please see full publication below for more information.
